Codex DNA Gross Profit

Codex DNA (DNAY) currently reports a gross profit of $8.9M as of September 2024. That compares with $16M in the prior-year period — down 45.5% year over year. That is below the Healthcare sector average of $65B. Use the charts on this page to explore Codex DNA's gross profit history and peer comparisons.

Codex DNA's gross profit decreased from $16M to $8.9M — a 45.5% year-over-year decrease (period ending September 2024). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Codex DNA's gross profit of $8.9M is lower than the Healthcare sector average of $65B. That is roughly 100.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Codex DNA reported $8.9M in gross profit as of September 2024. That compares with $16M in the prior-year period — down 45.5% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current gross profit of $8.9M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $65B. From there, open related valuation or income-statement pages for Codex DNA, and consider following DNAY for alerts when major investors trade the stock.